COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the type 2/Th2 polarized skin disease, atopic dermatitis (AD).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Allergy Clin Immunol Pract

Title: The journal of allergy and clinical immunology. In practice

Publisher: Elsevier BV

ISSN (Electronic): 2213-2201

Publication date (Electronic): January 2022

Volume: 10

Issue: 1

Affiliations

[1 ] Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY.

[2 ] Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY; Touro College of Osteopathic Medicine, New York, NY.

[3 ] Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Biomedical Engineering, the University of Mississippi, University, Miss.

[4 ] Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: emma.guttman@mountsinai.org.

Article

Publisher Item ID: S2213-2198(21)01203-4

DOI: 10.1016/j.jaip.2021.10.050

PMC ID: 8558098

PubMed ID: 34737108

SO-VID: 7f36bac8-880c-4ed2-802d-08fea75c3676

History

Keywords: Th2,Dupilumab,COVID-19,Biologics,Atopic dermatitis,SARS-CoV-2

Data availability:

Keywords: Th2, Dupilumab, COVID-19, Biologics, Atopic dermatitis, SARS-CoV-2

Comments

Comment on this article

scite_

Cited by 17

See all cited by

- Version 1